Neurology Brands

Sanofi Genzyme's oral disease-modifying therapy (teriflunomide) for relapsing forms of multiple sclerosis, FDA approved September 12, 2012, that works by inhibiting dihydroorotate dehydrogenase (DHODH) to selectively reduce proliferating lymphocytes driving MS inflammation.

Brand name for rivastigmine, a prescription cholinesterase inhibitor developed by Novartis for treating mild-to-severe Alzheimer's disease and Parkinson's disease dementia.

Prescription immunosuppressant medication for treating relapsing-remitting multiple sclerosis, manufactured and marketed by Novartis.

Pfizer's brand name for pregabalin, a neuropathic pain and fibromyalgia treatment approved by the FDA in 2004, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.